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Abstract In an attempt to create the possibility of stable, long
acting, intravascular anticoagulation, low molecular weight
heparin was modified by introducing a sulfhydryl group into
the molecule (LMWH-SH). Human erythrocytes were cova-
lently grafted with LMWH-SH by the use of a heterobifunc-
tional coupling reagent which reacts with the SH group of
LMWH-SH and surface exposed amino groups of erythrocytes
now called ‘heparinocytes’ (HC). HC were morphologically
indistinguishable from untreated erythrocytes and displayed
identical osmotic resistance. The functionality of HC was
analyzed by classical coagulation tests in which they dose
dependently inhibited clot formation. HC were also functional in
recalcified whole blood inhibiting thrombin formation as assessed
by the cleavage of the chromogenic substrate S-2238. The system
appears applicable as a potential autologous, long-term anti-
coagulant treatment or prophylaxis.
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1. Introduction
Heparin and its low molecular weight derivatives (LMWH)
are widely used to treat and prevent thromboembolic disor-
ders [1]. Despite its generic name, LMWH represents a class
of heterogeneous molecules generated by chemical or enzy-
matic depolymerization of unfractionated heparin with a typ-
ical molecular weight distribution, covering the range of ap-
proximately 1800^12 000 with an average of 5000 [2]. The
molecular weight and the anticoagulatory properties of the
various preparations di¡er conspicuously not only from un-
fractionated heparin but also between themselves. The advan-
tages of LMWH include a better bioavailability, a longer half-
life in plasma, a superior reproducibility of the weight-ad-
justed anticoagulation response, a more selective way of ac-
tion and a better side-e¡ect pro¢le [3^6].
It would be useful to have a way to produce anticoagula-
tion with a stable e¡ect over several days without the need for
daily injection(s) and with a strictly intravascular mode of
action. Eruthrocytes (EC) with an active substance immobi-
lized on their surface might be good candidates for this pur-
pose. EC have been used earlier for such purposes: covalently
bound ¢brin monomers were used for the detection of ¢bri-
nogen^¢brin intermediates [7,8]. More recently, Coller et al.
[9] produced so-called thromboerythrocytes by covalently at-
taching arginine-glycine-aspartic acid (RGD) peptides of dif-
ferent lengths onto the surface of EC, more precisely to the
amino groups of glycophorin A. Such thromboerythrocytes
were functional in aggregation tests in vitro and in the animal
model [10].
The present study describes a new modi¢cation of LMWH
which displays a thiol group suitable for chemical coupling.
This property was applied to covalently bind the modi¢ed
LMWH onto the surface of EC with the ultimate aim of
generating a model for anticoagulation exclusively con¢ned
to the circulating blood and with the perspective of a long-
term anticoagulant e¡ect.
2. Materials and methods
2.1. Materials
Coagulometer according to Schnitger-Gross was from Amelung,
Lemgo, Germany; dialysis membranes, cut-o¡ 10 000^20 000, Serva-
por, Serva, Heidelberg, Germany; diode array spectrophotometer,
Hewlett Packard HP 8452A, Waldbronn, Germany; £ow cytometer,
EPICS Pro¢le II, Coulter Corp., Hialeah, FL, USA; microtiter plate
reader, SLT-Labinstruments EAR 340 AT, Gro«dig, Austria; thermo-
mixer 5437, centrifuge 5415c, Eppendorf, Hamburg, Germany; APTT
reagent, actin FS, Baxter, Miami, FL, USA; cystamine, dithionitro-
benzoate, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, LMWH,
Fluka, Buchs, Switzerland; £uorescein-conjugated anti-rabbit anti-
bodies, Sigma, St. Louis, MO, USA; rabbit anti-human AT-III anti-
serum, Behring, Marburg, Germany; S-2238, human ¢brinogen, Frag-
min, Heparin Coatest, Chromogenix, Mo«lndal, Sweden; thrombin,
Diagnotek AG, Liestal, Switzerland; trinitrobenzoic acid, monothio-
glycerol, Serva, Heidelberg, Germany. All other reagents were ob-
tained in the highest purity grade available commercially.
2.2. Synthesis of a thiol derivative of LMWH
About 41 Wmol of LMWH (calculations made on the basis of an
average molecular weight of 5000) were dissolved in 4 ml 20 mM
morpholinoethanesulfonic acid (MES), pH 5, and 1.6 ml dimethylsulf-
oxide (DMSO). Cystamine (245 Wmol) was dissolved in 0.4 ml 20 mM
MES, pH 5, and added to the LMWH solution. The reaction was
started by the addition of 250 Wmol EEDQ dissolved in 0.4 ml DMSO
under vigorous stirring. The pH was corrected to 5 by the addition of
1 M HCl and the mixture was left at room temperature without
stirring overnight. The solution was then dialyzed against 1 l 0.1 M
NaPi, pH 9, for 1 day with changes of bu¡er after 4 and 10 h. The
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reduction of cystamine was achieved by the addition of 55 mM mono-
thioglycerol (¢nal concentration). To improve reduction, a few grains
of sodium dithionite were also added to the solution which was left
for 2 h at room temperature. The solution was dialyzed against 1 l 50
mM NaPi, pH 4.5, for 4 h, 1 l 25 mM NaPi, pH 4.5, for 4 h, and
¢nally against 1 l of double distilled water overnight. After an addi-
tional change of dialysis water for 4 h the solution was lyophilized.
The content of substance was measured by weight and by a colori-
metric method with Azur A [11]; SH group content was determined
by reaction with dithionitrobenzoate [12]. The molar ratio between
LMWH and SH groups was 0.9^1.5. The powder was kept under
argon at room temperature until use. Under these conditions the
substance was stable for over a year.
2.3. Preparation of heparinocytes (HC)
Citrated blood (25 ml, 1:10, 110 mM sodium citrate) was taken
from healthy volunteers taking no medication by venipuncture of an
antecubital vein in the supine position, in polypropylene syringes
(1U5 ml, 2U10 ml). A standardized pressure of 50 mm Hg was
installed using a sphygmomanometer for less than 1 min. One 10 ml
syringe was kept at 4‡C until use for recalci¢cation experiments (see
Section 2.7); the second 10 ml syringe was used as a source of plasma
(centrifugation: 2000Ug for 20 min); the 5 ml syringe was used as a
source of washed EC. Washed EC were prepared according to Coller
et al. [9] and resuspended in 140 mM NaCl, 5 mM KCl, 10 mM
glucose, 10 mM sodium phosphate, pH 7.4 (bu¡er A), to the original
whole blood volume. Based on work of Coller et al. [9] we estimated
the maximal amount of amino groups accessible to the succinimidyl
ester chemistry on the EC surface to be about 10 nmol/ml EC at a
hematocrit of 40%. Typically, an excess of 200 times of LMWH-SH
on a molar basis over the maximally accessible number of amino
group content of EC was chosen, whereas the molar ratio between
the crosslinker succinimidyl 6-maleimidylhexanoate (EMCS) and
LMWH-SH was 1.
2.4. Osmotic resistance
Control EC and HC were added to decreasing concentrations of
NaCl ranging from 8.5 to 0 g/l in double distilled water. After 20 min
at room temperature the solutions were gently mixed and centrifuged
at 1700Ug for 10 min. The optical density of the supernatants was
read at 540^546 nm to determine the concentration of free hemoglo-
bin. The measurement was repeated after 24 h during which time the
cells were kept at 4‡C.
2.5. Flow cytometry
HC (10 Wl) were diluted 1:10 with bu¡er A and incubated with 50
Wl autologous plasma for 10 min at 37‡C. In this step antothrombin
III (AT-III) present in the plasma was allowed to bind to the LMWH
molecules covalently bound to the EC surface. After centrifugation
(8000Ug for 2 min) the HC pellet was resuspended with 100 Wl of
bu¡er A (this step was repeated twice) and incubated with 10 Wl of
anti-human AT-III rabbit antibodies for 1 h at 37‡C. HC were washed
as before and incubated with anti-rabbit £uorescein isothiocyanate
(FITC)-labeled goat antibodies for 1 h at 37‡C. For £ow cytometry
samples were washed as described before, resuspended to 100 Wl and
further diluted at 1:100 with bu¡er A. Control experiments were
performed (i) by omitting the primary antibody, (ii) by omitting the
secondary antibody, (iii) using a non-speci¢c rabbit IgG as primary
antibody, and (iv) using untreated EC instead of HC.
2.6. Coagulometric assays
Thrombin time (TT) and activated partial thromboplastin time
(APTT) were measured with a coagulometer according to Schnitger-
Gross. For the TT, 100 Wl plasma were incubated with 100 Wl of bu¡er
B (50 mM Tris^HCl, 100 mM NaCl, pH 7.4 at room temperature)
and varying amounts of EC or HC for 3 min at 37‡C. Coagulation
was started by the addition of 100 Wl of bovine thrombin solution (10
U/ml). For the APTT, 50 Wl of plasma was incubated with 50 Wl
APTT reagent, 100 Wl of bu¡er B and varying amounts of EC or
HC for 2 min at 37‡C. Coagulation was started by the addition of
100 Wl 20 mM CaCl2.
2.7. Thrombin generation in whole blood after recalci¢cation
Citrated whole blood (1.5 ml) was recalci¢ed by the addition of 20
Wl 1 M CaCl2 ( = time zero) under vigorous vortexing for 2^3 s, and
distributed as 200 Wl aliquots in ¢ve Eppendorf tubes. The tubes were
incubated at 37‡C in an Eppendorf thermomixer under continuous
agitation at 600 rpm. At the times indicated, the samples were centri-
fuged for 2 min at 8000Ug. 10 Wl plasma was added to 275 Wl of 100
mM NaCl, 50 mM Tris, pH 8.5, and 15 Wl 2 mM chromogenic sub-
strate S-2238 in a microtiter plate. Absorbance was read at 405 nm at
30 s intervals for 3^4 min in a microtiter plate reader. Samples were
measured in duplicate and rates were calculated from kinetic data.
3. Results
3.1. LMWH modi¢cation
The LMWH (Fluka, art. no. 51550) had an anti-factor Xa
activity of 166^210 U/mg as assessed by Chromogenix Coatest
spectrophotometric determination (n = 3). The measurements
Table 1
Coagulation tests: inhibitory e¡ect of heparinocytes
Test (s)
Thrombin time
Control, no addition 21.4 20.7 18.9 18.6 20.0 15.6
Third wash solution 19.2 19.0 19.1 18.6 19.1 18.6
Control EC, 100 Wl 19.0 18.8 17.4 16.6 21.1 20.7
HC 10 Wl 196.6 215.0 45.8 71.4 105.4 43.6
HC 20 Wl s 1000 s 1000 s 1000 s 1000 s 1000
HC 30 Wl s 1000 s 1000 s 1000 s 1000 s 1000
Activated partial thromboplastin time
Control, no addition 31.0 30.7
HC 60 Wl 301.0 317.1
HC 80 Wl 767 486
HC 100 Wl s 1000 s 1000
Activated clotting time (RACT cuvettes)
Control, citrated whole blood 135 131 129
10% HC 151 143 171
25% HC 182 174 198
50% HC 212 217
100% HC 252 252
Tests were performed as described in Section 2. In order to assess that HC during their preparation were well washed and free of unbound
LMWH, the supernatants were routinely tested by thrombin time for its presence. The values obtained from the third supernatant of the wash-
ing procedure showed that HC were free of unbound LMWH. Addition of unmodi¢ed EC to the test solution did not signi¢cantly modify the
control times. Incremental additions of HC to the di¡erent test solutions showed a prolongation of the clotting times. In the presence of su⁄-
cient amounts of HC the test solutions were also unclottable. The results were representative of two to six di¡erent preparations of HC.
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were calibrated using LMWH Fragmin (Kabi) as standard
which has an anti-factor Xa activity of 156 U/mg. The intro-
duction of cystamine molecules in LMWH was catalyzed by
the carboxyl group-activating reagent EEDQ (Fig. 1). A mol-
ecule of LMWH is composed of four to six pentasaccharide
units each of which have two carboxyl groups. The intact
presence of these groups in at least one pentasaccharide unit
is essential to preserve anti-factor Xa activity. The modi¢ca-
tion used in this work and the subsequent reduction of the
disul¢de bridge of cystamine resulted in the loss of 9 50% of
the original anti-factor Xa activity. The molar ratio between
SH groups and LMWH varied from 0.9 to 1.5 (n = 6). This
indicates that only a part of the essential carboxyl groups
were modi¢ed and therefore the modi¢ed LMWH still pos-
sessed valuable activity.
3.2. Clotting tests
Each preparation of HC and the last two wash supernatants
were routinely tested for the prolongation of TT as described
in Section 2. Control EC (i.e. EC which were incubated and
washed as HC without addition of crosslinker but in the pres-
ence of LMWH-SH) and HC were resuspended with wash
bu¡er A to their original concentration in whole blood (hem-
atocrit 40%). As shown in Table 1, control EC gave TTs very
similar to control times obtained with plasma alone whereas
HC showed a dose dependent prolongation of the TT. On
average 20^30 Wl of HC in a total volume of 400 Wl was
su⁄cient to give unclottable TTs. Even smaller amounts of
HC also clearly prolonged the APTT and the activated clot-
ting time.
3.3. Thrombin generation in recalci¢ed whole blood
Increasing amounts of HC were added to autologous ci-
trated whole blood and after recalci¢cation, the thrombin
generation in plasma was measured using the chromogenic
substrate S-2238 (Fig. 2). When 20% of the red cells in whole
blood were HC, it was su⁄cient to block thrombin generation
completely over 60 min after recalci¢cation.
To further extrapolate the anticoagulatory potency of 20%
HC, experiments were performed in the presence of increasing
amounts of free LMWH (Fragmin; 156 anti-Xa U/mg) added
to the citrated whole blood before recalci¢cation. An equiv-
alent blockade of thrombin generation (as produced by 20%
HC) was achieved by 0.6 anti-Xa U/ml whole blood. This
means that fully modi¢ed blood at a hematocrit of 40% would
reach a functional potency as high as 3 anti-Xa U/ml. Pro-
phylactic anticoagulation reaches peak levels ofV0.2^0.4 anti
Xa U/ml 4^6 h after the injection and may reach up to 0.75
U/ml during therapy. Thus, heparinocytes may achieve the
levels required with a reasonable amount of blood modi¢ed.
3.4. Binding of AT-III to heparinocytes
The anticoagulatory mechanism of LMWH consists of in-
creasing the inhibitory constant of AT-III for its targets,
mainly factor Xa. Therefore HC must bind AT-III in orderFig. 1. Scheme of the LMWH modi¢cation.
Fig. 2. Kinetics of thrombin generation in recalci¢ed whole blood.
A: Open symbols represent the control experiment without any ad-
dition (a, n = 8), in the presence of free LMWH Fragmin 0.1, 0.3,
0.6 U/ml blood (E, O, 7, n = 2 for all other measurements).
B: Closed symbols represent a control experiment performed in the
presence of control EC (b), 5, 10, 20% HC (hematocrit 40%) mixed
with whole blood before recalci¢cation (F, R, 8).
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to exert their anticoagulatory e¡ect. This step was analyzed by
detecting the £uorescence of secondary antibodies directed
against anti-AT-III antibodies bound to HC (Fig. 3). Omit-
ting the incubation step with plasma or the anti-AT-III anti-
bodies resulted in negative controls as also seen for control
EC. In addition clotting tests (TT) using AT-III-depleted plas-
ma incubated with HC have shown that the coagulation times
were equal to the control times (not shown). Therefore we
conclude that (1) LMWH was indeed covalently bound to
the surface of EC and (2) the immobilized LMWH was still
functional; thus, the concept of ‘heparinocytes’ with the po-
tential of pure intravascular anticoagulation at a stable level
of heparin action was realized.
4. Discussion
The modi¢cation strategy of LMWH presented in this
study di¡ers substantially from the modi¢cations published
until now [11,13^16]. Under controlled conditions it was pos-
sible to modify carboxyl groups of LMWH leaving the major
amount of original anti-factor Xa activity (v50%). The cova-
lently coupled cystamine (H2N^CH2^CH2^S^S^CH2^CH2^
NH2) in a molar ratio of about 1 has the intrinsic advantage
of carrying two di¡erent chemical groups (^NH2 and ^SH)
that are easily coupled to other targets, i.e. in our study to the
surface of EC.
We have successfully attached LMWH to red cells by the
use of the heterobifunctional cross-linker EMCS. This strat-
egy has been used previously with small peptides by one of us
(J.H.B.) in Coller et al. [9], who showed that the main reactive
amino groups modi¢ed were located on glycophorin A. A
similar modi¢cation site can therefore be assumed in our ex-
periments. We con¢rmed that such modi¢ed EC were unaf-
fected by the procedure as shown by light microscopy, degree
of hemolysis and osmotic resistance, and this is also in agree-
ment with the results of Coller et al. [9]. HC were functionally
active in all coagulation tests used. In order to be closer to the
in vivo situation and not to exclude potential interactions of
red blood cells with other blood cells, we used a method of
measuring the thrombin generation in whole blood after re-
calci¢cation. The comparison of the e¡ect of free LMWH
with a known activity allowed us to quantify the anticoagu-
latory potency of HC although we cannot exclude a di¡erent
speci¢c activity of the covalently attached LMWH, since the
surface of EC displays a large number of carbohydrates.
Nevertheless, it was shown that HC exert anticoagulatory
properties very similar to free LMWH with the di¡erence
that LMWH bound to a ‘solid phase’ now has the potential
half-life of the red cells.
This in vitro model appears attractive because of its clinical
potential : (a) HC with the potential half-life of red cells would
allow a stable, prophylactic heparinization of up to 2^4
months, i.e. during the entire red cell life span; the gradual
disappearance seems to be an additional, interesting option.
Ideally, a patient could donate 20^30 ml of blood, his red cells
would be washed, modi¢ed with LMWH-SH and reinfused
within a few hours. Such a patient would remain anticoagu-
lated over the period of about 2 months as desired. This new
approach could make today’s 1^2 injections for anticoagula-
tion unnecessary and could o¡er stable levels of anticoagula-
tion over longer periods of time. (b) HC will exert their anti-
coagulatory activity strictly intravascularly and there should
be less interaction with endothelial cells with the advantage
that the dosage could be calculated more precisely. Ideally,
primary hemostasis due to small vascular injuries could pro-
ceed una¡ected because HC have no immediate access to
these sites as easily as free LMWH molecules, particularly
in a laminar £ow. On the other hand they would inhibit intra-
vascular initiation and progression of clotting. This could im-
ply the potential of anticoagulation without an increased ex-
cess bleeding risk.
The issues that we will address in a second step include the
survival of HC in vivo (an animal model with ‘thrombo-
erythrocytes’ showed encouraging results [10]) ; and just re-
cently, preliminary data of a rabbit jugular model of throm-
bosis indicated that the heparinocytes appeared to be very
e¡ective in vivo as well [17].
A realistic scenario seems to be the following clinical appli-
cation: a patient comes in for orthopedic surgery and there-
fore receives a single dose of modi¢ed autologous erythrocytes
and then remains prophylactically anticoagulated for at least
4 weeks, without the need for daily injection of warfarin treat-
ment. The immunogenicity, the potential proteolytic cleavage
of the new ligand in vivo, and, most importantly, the thera-
peutic e¡ectiveness and its reversal e.g. by protamine will be
additional, important questions. Preliminary in vitro data sug-
gest partial reversibility by protamine (data not shown).
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